$60 million AstraZeneca milestone payment for Eccogene
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca (LSE: AZN), which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program.
VISTA (NCT06579092) and SOLSTICE (NCT06579105) are two global Phase IIb multicenter trials assessing the efficacy and safety of ECC5004/AZD5004, administered orally, once daily, to participants who are obese or overweight with at least one weight-related comorbidity and type 2 diabetes, respectively.
AstraZeneca licensed the global rights to ECC5004/AZD5004 from Eccogene in November 2023, for which the company received an upfront payment of $185 million is eligible for up to $1.825 billion in future milestones, as well as royalty payments. Eccogene retains co-development and co-commercialization rights to ECC5004/AZD5004 in China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze